China To Survey Cost And Market Pricing Of Medical Insurance Drugs
This article was originally published in PharmAsia News
Executive Summary
In tandem with China's health care reform and national basic medicine system implementation, National Development and Reform Commission recently announced that it will conduct a survey on market prices and production costs of all 1,031 Western medicines and 823 TCMs in the catalogs of national basic medical insurance and work injury insurance. The study includes product costs, market price, tender price, provincial pricing and recorded price. NDRC said that clarification about medicine cost and pricing will help the government adjust its pricing policy in a timely manner. According to Beijing Municipal Commission of Development and Reform, the city has identified Beijing Pharmaceutical, Beijing Yibao Quanxin Pharmacy, Peking University Third Hospital, Beijing No.6 Hospital and Beijing Jinsong Hospital as subjects for the survey. (Click here for more - Chinese Language)
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.